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Abstract
Despite advances in elucidating the pathogenic factors respon-
sible for its development, systemic sclerosis remains complex and
poorly understood, and treatment options are limited. Multi-
disciplinary collaborative efforts are needed to better characterize
clinical and prognostic parameters and to design and implement
large-scale clinical trials in well defined populations with therapies
that target potential disease modulators.
Introduction
Systemic sclerosis (SSc) is a multisystem connective tissue
disease (CTD) of unknown aetiology that is characterized by
inflammation, vasculopathy and fibrosis of the skin and visceral
organs. The condition is clinically diverse, both in terms of the
burden of skin or organ based disease and the rate of
progression within different manifestations. Some aspects of
the disease progress rapidly, whereas others may stabilize after
initial decline. Skin involvement often improves spontaneously
but this is much less likely for visceral complications. Although
some significant advances in therapy have been made during
the past two decades, SSc remains a challenging disease for
which outcomes are often unsatisfactory.
Complexity of the pathophysiology of systemic
sclerosis and other connective tissue diseases
Endothelial dysfunction appears to be an early event in the
underlying pathophysiology of inflammatory and fibrotic
CTDs, including SSc, and patients with SSc often exhibit
early signs of vasculopathy. This is most frequently apparent
as Raynaud’s phenomenon, which may precede other
symptoms by several years. Levels of a number of cellular
mediators are elevated in patients with SSc, including
chemokines (for example, CC chemokine ligand 2) [1],
endothelin (ET)-1 [2], connective tissue growth factor (CTGF)
[3] and natural tissue inhibitor of metalloproteinases, whereas
the data are conflicting for other mediators, such as trans-
forming growth factor (TGF)-β (see the review by Denton [4]
in this supplement) and matrix modulating proteins (for
example, matrix metalloproteinases). As well as the regulation
of extracellular matrix deposition [5,6], these compounds are
critical for regulation of cytokines and chemokines, which in
turn play significant roles in the progression of CTDs.
Dysregulated angiogenesis is also an important process in
the pathophysiology of many CTDs, although the precise
picture does appear to vary between specific diseases.
Whereas in rheumatoid arthritis the process is well
characterized, with inducers of angiogenesis outweighing
inhibitors [7], in SSc there is evidence of both increased and
decreased angiogenesis, and the real challenge will be how
to manipulate selectively the positive and negative effects of
mediators to realize any therapeutic advantage.
There is evidence of a genetic component to SSc. Our
understanding of potential genetic factors has improved over
the past few years, and SSc appears to represent a
collection of phenotypes rather than a single disease entity.
Although there remains much to learn with respect to direct
genetic perturbations that may initiate disease, candidates
apparently important in the pathophysiology of SSc, such as
Fli1 [8], are beginning to emerge [9].
Fibrosis, characterized by excessive extracellular matrix
accumulation, is a common feature of many CTDs, most
notably SSc. Experimental studies suggest that a complex
network of intercellular interactions involving endothelial cells,
epithelial cells, fibroblasts and immune cells, using an array of
molecular mediators, drive the pathogenic events that lead to
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fibrosis. It is likely that a variety of mediators act in concert to
determine the profibrotic microenvironment within affected
tissues in SSc. Although TGF-β is a prototypic stimulator of
fibrosis, it appears that other mediators such as CTGF and
ET-1, interleukin-4, interleukin-13 and chemokines all are
potentially involved in determining differentiation of fibroblasts
toward a myofibroblast phenotype.
Thus, there is evidence to support a complex interplay
between many of these molecules and key cell types, which is
dependent both on the severity of disease and on the type of
tissue affected. However, better appreciation of the complex
pathophysiology of the disease and the many convergent
pathways is now leading to a greater understanding of where
and how to intervene. This, in turn, is leading to identification
of targets and development of advanced therapies for future
management of this patient population. Despite this progress,
a single cure or even a truly effective therapy currently remains
elusive, although advances are being made, particularly with
therapies that target the vasculopathy.
Targets for therapeutic intervention
Any of the molecules described in the discussion above could
represent a potential therapeutic target in the treatment of
SSc, with therapies targeting each of the three cardinal
features of CTD: inflammation/autoimmune activation, vasculo-
pathy and fibrosis. To date, clinical success with therapies
against key profibrotic mediators such as CTGF and TGF-β
has not been demonstrated, although studies are ongoing and
these mediators remain logical targets. In contrast, there has
been much greater success in treating the vasculopathic
manifestations of the disease. Angiotensin-converting enzyme
inhibitors have revolutionized treatment of SSc renal crisis;
prostacyclin analogues appear to be effective in healing digital
ulcers and improving Raynaud’s phenomenon; and, more
recently, treatment with the dual specificity ET antagonist
bosentan has been promising for SSc-related pulmonary
arterial hypertension (PAH) and ischemic digital ulceration.
Several published studies point toward benefit from bosentan
in patients with PAH related to CTD [10-12]. In addition, two
large clinical trials [13,14] have confirmed that development
of new ischaemic digital ulcers is reduced by bosentan. In
addition,  post hoc analyses of trials with the single ET
receptor subtype A antagonist sitaxentan (a drug licensed for
the treatment of PAH in the European Union) have also
suggested benefit in patients with PAH-CTD [15]. Another
single ET receptor subtype A antagonist has also been
approved recently in the US. Given these data, it is not
surprising to see the association of ET-1 with vascular
features of sarcoidosis, and evidence supporting a role for
ET-1 in atherosclerotic or inflammatory changes in vasculitis
or the vasculopathy of rheumatoid arthritis and systemic lupus
erythematosus. As such, there are promising indicators to
suggest that ET-1 plays a role, and the challenge remaining is
how best to study it in both preclinical and clinical settings.
Although there are some interesting preclinical data
suggesting a potential role for ET-1 in nonvascular manifes-
tations of CTD, there are no robust clinical data supporting
ET receptor blockade as an effective strategy. SSc has a
complex pathophysiology, and it is important to remember
that the many candidate mediators that drive the disease are
likely to interact extracellularly and through convergent and
interacting intracellular signalling pathways. The final
biochemical events that occur in fibrosis may be triggered by
multiple pathways, and dissection of the aberrant regulation
of extracellular matrix deposition in SSc and other CTDs
represents an immediate challenge for translational research.
The review by Abraham and Distler [16] (in this supplement)
highlights the overlap and convergence of signalling
pathways activated within cells in response to several
candidate mediators of fibrosis and vascular damage. This
would seem to support combination therapy as an
appropriate approach to managing this complex disease. A
major consideration when manipulating any of these
pathways, and in particular when attempting to target several
pathways with combination therapy, is safety.
Future studies in systemic sclerosis
Targeted therapy for nonvascular complications of SSc is an
attractive goal. In view of its frequency and clinical impact,
interstitial lung disease (ILD) is of high priority for study.
However, it is clear from recent trials that study of this patient
population presents challenges, and lessons must be learned
from previous studies in which the selected trial population
was too stable for any treatment effect to be detectable [17].
Thus, before any new trial in this area can be successful, two
important needs must be met.
The first of these is the need for improved outcome measures
that are validated for use in the selected patient population.
Unfortunately, beyond right heart catheterization, outcome
measures for PAH-CTD (particularly PAH-SSc and SSc-ILD),
which are necessary for the design of such studies, are
poorly defined and those available are at best only partially
validated. Thus, there is an urgent need for a structured
approach to define end-points that take into account the
methodological problems associated with possible CTD-
specific confounding factors (for instance, musculoskeletal
problems, joint contractures, fatigue and de-conditioning,
which may affect cardiopulmonary testing) [18,19].
The second need is the requirement for effective ways to
characterize the disease and to assess the severity of
disease. This is complicated by the nature of disease, which -
as described above - is characterized by periods of rapid
decline and spontaneous periodic improvement, as well as
surprising periods of stability.
One of the major challenges in clinical trials of potential SSc
therapy is the need to enrich study cohorts with patients who
have progressive disease in skin or lung, or who will have aPage 3 of 3
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high event rate during a clinical trial. Clinicians are faced with
the conundrum of balancing the overriding belief that the
disease must be treated early with the fact that outcomes of
early-stage disease are especially variable. The challenge
now lies in identifying factors that may allow clinical trial
populations to be enriched with such patients. Ongoing
studies have suggested that the development of scleroderma
renal crisis may distinguish a patient population with
progressive disease in which a treatment effect may be
expected. Although we know that scleroderma renal crisis,
once a universally fatal complication of SSc, is now treatable
with angiotensin-converting enzyme inhibitors [20], it is
nevertheless a marker of progressive disease and may be one
means of selecting an appropriate population. There would
be some rationale for evaluating ET receptor antagonism in
this patient population, because there are many
histopathological similarities between the arterial disease of
SSc in the pulmonary, digital and renal vascular beds.
Conclusion
It is becoming increasingly apparent that SSc is a highly
complex disease. However, advances are being made in
elucidating SSc and other CTDs, and there are now options
available to target certain aspects of disease, particularly
vasculopathic manifestations, with agents such as ET
receptor antagonists. The complex nature of the disease
makes it ideal for a multidisciplinary approach to therapy.
Undoubtedly, early identification and aggressive management
are likely to improve long-term outcomes. Efforts are ongoing
to establish registries, to improve screening protocols and to
raise awareness within the rheumatology community of the
life-threatening manifestations of this disease, which, in turn,
will hopefully lead to better management in the future.
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